Eurosurv. Influenza vaccine effectiveness against A(H3N2) during the delayed 2021/22 epidemic in Canada

[tetano]

• Shinhye Kim[SUP]1[/SUP] , Erica SY Chuang[SUP]1[/SUP] , Suzana Sabaiduc[SUP]1[/SUP] , Romy Olsha[SUP]2[/SUP] , Samantha E Kaweski[SUP]1[/SUP] , Nathan Zelyas[SUP]3[/SUP] , Jonathan B Gubbay[SUP]2,4[/SUP] , Agatha N Jassem[SUP]1,5[/SUP] , Hugues Charest[SUP]6[/SUP] , Gaston De Serres[SUP]6,7,8[/SUP] , James A Dickinson[SUP]9[/SUP] , Danuta M Skowronski[SUP]1,5[/SUP]

Influenza virus circulation virtually ceased in Canada during the COVID-19 pandemic, re-emerging with the relaxation of restrictions in spring 2022. Using a test-negative design, the Canadian Sentinel Practitioner Surveillance Network reports 2021/22 vaccine effectiveness of 36% (95% CI: −38 to 71) against late-season illness due to influenza A(H3N2) clade 3C.2a1b.2a.2 viruses, considered antigenically distinct from the 3C.2a1b.2a.1 vaccine strain. Findings reinforce the World Health Organization’s decision to update the 2022/23 northern hemisphere vaccine to a more representative A(H3N2) clade 3C.2a1b.2a.2 strain.

https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2022.27.38.2200720#html_fulltext